pert diagram
PERT diagram (Click to zoom)

MIROCALS aims to perform a novel intervention study with the potential to:

  • halt disease progression
  • test the proof of concept that biomarkers can accelerate future intervention studies
  • provide unique insights on disease pathogenesis identifying novel targets for intervention.

The workprogramme has been structured in 7 workpackages (WPs):

WP2 and WP3 relate to the performance of the clinical trial

Work package 2: Clinical trial implementation
WP2 aim at designing, getting approval and organizing the clinical trial.

Work package 3: Clinical trial conduct
In this WP, the clinical trial will be carried out in compliance with GCP/GCLP rules, to demonstrate the efficacy and safety of ultra-low-dose IL-2 for patients with recently diagnosed ALS.

WP4, WP5 and WP6 relate to the specific laboratory investigations using CSF and blood samples collected during the trial to get better insights into the effects of riluzole and low dose IL-2 in ALS patients.

Work package 4: Deep immuno-phenotyping
WP4 aims to establish the effect of low dose IL-2 on key effectors and regulators of the neuro-inflammatory process and establish their relationship with treatment responses and disease activity.

Work package 5: Brain Biomarkers
The main focus of this WP will be on neurofilaments, whose dynamic of release into biological fluids reflects the progressive cytoskeletal break-down of neurons and axons.

Work package 6: Genomics and Transcriptomics
The main objective of WP6 is to establish the changes in transcriptomic profiles in response to both riluzole and IL-2 treatment and to characterise the gene expression signatures of responders to IL-2 versus those of non-responders.

WP1 and WP7 will ensure the project management as well as organizing the dissemination of the project’s results to patients and other stakeholders.

News

MIROCALS 1st General Assembly meeting in Brighton, June 9 & 10th 2016

This meeting gathered all MIROCALS partners for presenting the progress made since the launch of the project a year ago as well as the next achievements for the coming year. 

First participant recruited to MIROCALS trial

The MIROCALS consortium is delighted to announce that the first participant has been recruited to the MIROCALS trial, at Hospices Civils de Lyon, France.

Read more.

MIROCALS kick-off meeting in Paris, September 17-18th 2015

This meeting gathered all MIROCALS partners for fine-tuning the planned work programme, in the presence of the EC project officer, and members of the Independent Scientific Advisory Board of the project.

europe

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No. 633413.